Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13214
Abstract: Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer. FoundationOne® Liquid CDx (F1L CDx), a non‐invasive in vitro… read more here.
Keywords: positive solid; fusion positive; ntrk fusion; treatment ... See more keywords
China Special Issue on Gastrointestinal Tumor-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of cancer"
DOI: 10.1002/ijc.34522
Abstract: Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers and targets of TRK inhibitors in solid tumors. Little is known about NTRK fusion in Chinese patients with pan-cancer. This study investigated the prevalence… read more here.
Keywords: circulating tumor; fusion; ntrk fusion; treatment ... See more keywords
EPS15–NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03416-2
Abstract: Depending on the clinical scenarios, merely 0.1–3.3% NTRK fusions are demonstrated in lung cancer, but the remarkable efficacy of Trk inhibitors offers a possibility to use NTRK fusion as antitumorigenic target (Harada et al. 2020).… read more here.
Keywords: ntrk fusion; eps15 ntrk1; lung; fusion ... See more keywords
NTRK fusion-positive cancers and TRK inhibitor therapy
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0113-0
Abstract: NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the… read more here.
Keywords: ntrk fusion; trk inhibitors; trk; fusion ... See more keywords
S100 and Pan-Trk Staining to Report NTRK Fusion-Positive Uterine Sarcoma: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Gynecological Pathology"
DOI: 10.1097/pgp.0000000000000702
Abstract: NTRK fusion-positive uterine sarcoma is a recently recognized mesenchymal tumor that is defined by its morphologic resemblance to soft tissue fibrosarcoma, NTRK gene rearrangements, and potential response to Trk inhibition. Reported lesions affect premenopausal women… read more here.
Keywords: fusion positive; uterine sarcoma; pan trk; fusion ... See more keywords
Entrectinib Effective across NTRK Fusion-Positive Cancers.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-156
Abstract: Entrectinib may be an effective therapy for patients with NTRK fusion-positive solid tumors, regardless of tumor type. In a combined analysis of phase I and phase II trials, more than half of patients responded to… read more here.
Keywords: fusion positive; across ntrk; entrectinib effective; ntrk fusion ... See more keywords
Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report
Sign Up to like & getrecommendations! Published in 2021 at "Case Reports in Oncology"
DOI: 10.1159/000521158
Abstract: While neurotrophic tropomyosin receptor kinase (NTRK) fusions represent rare oncogenic drivers ( read more here.
Keywords: fusion; cns; sarcoma; ntrk fusion ... See more keywords
NTRK Fusion-Positive Congenital Spinal Glioblastoma treated with Carboplatin, Etoposide, and Larotrectinib
Sign Up to like & getrecommendations! Published in 2021 at "Pediatrics"
DOI: 10.1542/peds.147.3_meetingabstract.874
Abstract: Introduction Primary spinal glioblastoma multiforme (GBM) is a rare central nervous system tumor accounting for less than 3% of pediatric central nervous system tumors. The congenital form of this malignancy is even more unusual. Here… read more here.
Keywords: fusion positive; glioblastoma; spinal glioblastoma; ntrk fusion ... See more keywords